First Trust Advisors LP increased its position in shares of Retrophin Inc (NASDAQ:RTRX) by 131.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 160,878 shares of the biopharmaceutical company’s stock after purchasing an additional 91,513 shares during the period. First Trust Advisors LP owned approximately 0.39% of Retrophin worth $4,622,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in RTRX. PNC Financial Services Group Inc. lifted its holdings in Retrophin by 1,404.9% during the 2nd quarter. PNC Financial Services Group Inc. now owns 272,328 shares of the biopharmaceutical company’s stock worth $7,424,000 after purchasing an additional 254,232 shares during the last quarter. BlackRock Inc. lifted its holdings in Retrophin by 7.7% during the 2nd quarter. BlackRock Inc. now owns 3,512,643 shares of the biopharmaceutical company’s stock worth $95,754,000 after purchasing an additional 249,833 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Retrophin by 1,502.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 199,377 shares of the biopharmaceutical company’s stock worth $5,422,000 after purchasing an additional 186,932 shares during the last quarter. Macquarie Group Ltd. raised its holdings in Retrophin by 12.3% in the 2nd quarter. Macquarie Group Ltd. now owns 1,617,618 shares of the biopharmaceutical company’s stock valued at $44,096,000 after acquiring an additional 177,604 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its holdings in Retrophin by 61.8% in the 3rd quarter. Handelsbanken Fonder AB now owns 267,000 shares of the biopharmaceutical company’s stock valued at $7,671,000 after acquiring an additional 102,000 shares in the last quarter. 98.15% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ RTRX opened at $25.82 on Thursday. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -17.09 and a beta of 1.19. The company has a quick ratio of 4.99, a current ratio of 5.04 and a debt-to-equity ratio of 0.60. Retrophin Inc has a fifty-two week low of $20.09 and a fifty-two week high of $33.00.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.39). The company had revenue of $40.70 million during the quarter, compared to analyst estimates of $44.36 million. Retrophin had a negative net margin of 69.38% and a negative return on equity of 35.43%. Retrophin’s revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.15 earnings per share. As a group, equities research analysts forecast that Retrophin Inc will post -2.67 EPS for the current fiscal year.

In other news, SVP Elizabeth E. Reed sold 2,500 shares of the business’s stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $23.73, for a total transaction of $59,325.00. Following the completion of the transaction, the senior vice president now owns 20,627 shares of the company’s stock, valued at approximately $489,478.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Steve Aselage sold 11,100 shares of the business’s stock in a transaction on Thursday, November 15th. The stock was sold at an average price of $24.03, for a total value of $266,733.00. Following the transaction, the chief executive officer now directly owns 259,433 shares of the company’s stock, valued at approximately $6,234,174.99. The disclosure for this sale can be found here. Insiders have sold a total of 48,100 shares of company stock valued at $1,247,658 in the last three months. 3.67% of the stock is owned by insiders.

Several equities analysts have weighed in on the company. BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a report on Tuesday, August 28th. Zacks Investment Research raised Retrophin from a “sell” rating to a “hold” rating in a report on Thursday, September 27th. ValuEngine raised Retrophin from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 7th. Canaccord Genuity assumed coverage on Retrophin in a report on Friday, August 17th. They issued a “buy” rating for the company. Finally, Nomura assumed coverage on Retrophin in a report on Monday. They issued a “buy” rating and a $57.00 price objective for the company. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $48.00.

WARNING: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/11/22/first-trust-advisors-lp-grows-position-in-retrophin-inc-rtrx.html.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Article: No Load Funds

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.